ライフサイエンスコーパス: grade 3

1 (73.7% vs 66.4%; P = .21), severe complications (Accordion grade >/=3, 23.05% vs 23.7%; P > .99), hospital stay (median:

2 ients receiving trastuzumab emtansine plus pertuzumab had a grade 3-4 adverse event (29 [13%] of 223 vs 141 [64%] of 219)

3 roup vs four [1%] of 378 patients in the control group) and grade 3-4 adverse events (52 [7%] patients vs 31 [8%] patient

4 Rates of grade 3-4 adverse events did not differ among regimens (P = .

5 The most common grade 3-4 adverse events were decreased neutrophil count (210

6 The most comment grade 3-4 adverse events were neutropenia (n=2 [5%]), hyperte

7 The most common grade 3-4 adverse events with a suspected association with lo

8 The most common grade 3-4 haematological adverse events reported, irrespectiv

9 The association with grade 4 or grade 3-4 health conditions was highly significant for all ph

10 Radioimmunotherapy toxicity consisted of grade 3-4 thrombocytopenia in 48 (84%) of 57 patients and neu

11 During enzalutamide retreatment, no grade 3-4 toxicities occurred in more than one patient.

12 New albumin, bilirubin, and alkaline phosphatase grade 3/4 toxicities were, respectively, 3%, 10%, and 0% for

13 8.1) CHCs of any grade, of which 4.7 (4.6-4.9) were CHCs of grade 3-5.

14 26 (39%) of 44 patients had grade 3 adverse events, but no grade 4 events were reported.

15 se were grades 1 and 2, with 26% of patients experiencing a grade 3 AE.

16 Incidence of grade >/= 3 AEs was 45% and 35%, respectively.

17 The most frequently observed grade 3 and 4 adverse events were transaminase increases (40%

18 Fewer grade 3 and 4 treatment-related adverse events were observed

19 with toxicity grade, with a significant difference between grade >/=3 and grade 0 patients (P = 0.02).

20 .02 to 1.13/Gy; P = .01) were significantly associated with grade >/= 3 cardiac events.

21 in women diagnosed with cervical intraepithelial neoplasia grade 3 (CIN3).

22 d cervical intraepithelial neoplasia (grade >/=2 [CIN2+] or grade >/=3 [CIN3+]).

23 de 0 or 1, 39% had steatosis grade 2, and 27% had steatosis grade 3; corresponding mean PDFF values were 9.8%+/-3.7%, 18.

24 Other grade 3 disorders included hepatobiliary and renal disorders

25 F-FLT uptake in these areas was much lower in patients with grade 3 fibrosis than in patients with grade 1 or 2 fibrosis.

26 dverse events (myositis in addition to grade 3 thyroiditis, grade 3 hepatitis, grade 3 pneumonia, and grade 4 myocarditis

27 ed in the idelalisib group compared with the placebo group (grade >/=3 infections and infestations: 80 [39%] of 207 vs 52

28 No grade 3 or 4 adverse events were reported in either study.

29 Fewer patients had treatment-related grade 3 or 4 adverse events with atezolizumab (90 [15%] of 60

30 Fifty-five percent of patients had grade 3 or 4 neurologic toxicities that completely resolved.

31 ase progression [DP], 13%) versus 33% of high-grade tumors (grade 3 or 4) (complete response, 0%; partial response, 33%;

32 The roots with radicular grooves (grade 3 or 4) were defined as Tome's anomalous root and these

33 The most common adverse events of grade 3 or higher during treatment were neutropenia (in 78% o

34 Adverse events of grade 3 or higher were reported in 87% of the patients in the

35 In the control group, the most frequently reported grade 3 or worse adverse events were diarrhoea (103 [21%] of

36 The most common adverse events of grade 3 or worse severity were anaemia (38 [19%] of 195 patie

37 Common grade 3 or worse toxic effects were related to the lymphodepl

38 st one of grade 3 thrombocytopenia, anaemia, or bleeding at grade 3 or worse, with palpable spleen of at least 5 cm and w

39 well tolerated with only 1 dose-limiting toxicity reported (grade 3 pneumonia at 20 mg/kg QW/Q2W); the MTD was not reache

40 itis in addition to grade 3 thyroiditis, grade 3 hepatitis, grade 3 pneumonia, and grade 4 myocarditis).

41 IMRT was associated with less >/= grade 3 pneumonitis (7.9% v 3.5%, P = .039) and a reduced ris

42 duction to less than 20 mg twice a day with at least one of grade 3 thrombocytopenia, anaemia, or bleeding at grade 3 or

43 m treatment-related adverse events (myositis in addition to grade 3 thyroiditis, grade 3 hepatitis, grade 3 pneumonia, an

44 Fifteen patients experienced grade 3 to 4 adverse events; the most common were fluid reten

45 treated with selinexor at 35 or 60 mg/m(2) The most common grade 3 to 4 drug-related adverse events were thrombocytopeni

46 e most frequently skin related, GI, endocrine, and hepatic; grade 3 to 4 select AEs occurred in 4% of patients.

47 After a median follow-up of 32 months, there were no grade 3 toxicities.

48 spective study, correctly classified 23 of 28 patients with grade >/=3 toxicity (sensitivity 82%) and 9 of 14 patients wi

49 Only one patient experienced a dose-limiting toxicity-grade 3 transient asymptomatic hyponatremia at the 1.0-mg/kg

50 Five (15%) patients had 11 grade 3 treatment-related adverse events; no single event occ